Jim Cramer -- Following Nelson Peltz Can Make You a Ton of Money

Sysco (SYY) - Get Report reported a "really terrific quarter," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on Monday's CNBC "Stop Trading" segment. He said the food distributor's stock has been on fire since activist investor Nelson Peltz took a stake and joined Sysco's board in August.

If investors had followed Peltz into the same stocks he disclosed in his last Securities and Exchange Commission filing, they would've topped the S&P 500, Cramer said. Peltz likes to "help management," Cramer said, and is a "very opportunistic, smart investor." That's one reason Sysco is a terrific company.

However, another stock, biotech Sarepta Therapeutics (SRPT) - Get Report , has become a "battleground" among analysts. Cramer noted Jefferies' negative take and Oppenheimer's upgrade.

There's a big short interest of 43% in Sarepta, he added. If its Duchenne muscular dystrophy treatment gets approved, the stock will have plenty of upside. If it doesn't get approved, there's not much else in the pipeline, Cramer said.

Despite a recent Food and Drug Administration panel review being negative on the treatment, some the agency's officials, notably Dr. Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, are more positive, according toTheStreet's Adam Feuerstein.

It's noteworthy the FDA seems to be taking a more passionate approach by talking to patients afflicted with this disease and their families, Cramer said.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.